CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Gustav A Christensen, President and Chief Executive Officer of Dyax, will present at the 12th Annual BIO CEO & Investor Conference, being held February 8-9th at The Waldorf-Astoria Hotel in New York, NY. Mr. Christensen will present a corporate progress report, including an update on the Company’s commercial activities for KALBITOR® (ecallantide) and clinical development programs. The Dyax presentation is scheduled for Monday, February 8th at 10:30 AM (ET).
